Sanofi to acquire 7.764% in Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, for $125m. "As all eyes are on prevention of infectious disease through vaccines, this is a pointed moment in time where we are called upon to seek innovative ways to protect public health. We are excited by the novel technology and expertise Translate Bio brings, and we believe that adding this mRNA platform to our vaccines development capabilities will help us advance prevention against current and future infectious diseases," Thomas Triomphe, Sanofi Pasteur Executive Vice President.